IP Library Granted Patent US 8,946,196
Granted Patent B2
US 8,946,196 · App. 14/041,593 · Granted Feb 3, 2015

Methods for synthesizing and purifying aminoalkyl tetracycline compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,196
App. No.
14/041,593
Granted
Feb 3, 2015
Kind
B2
Abstract

Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described.

Claims (35)

1. A method of purifying an alkylaminomethyl minocycline compound, comprising:

a) injecting a low pH aqueous solution of said alkylaminomethyl minocycline compound into a liquid chromatography device in a polar organic solvent gradient, and combining the product fractions;

b) adjusting the pH of said product fractions to 4.0-4.5;

c) washing said product fractions with a first non-polar organic solvent to form a first organic layer and a first aqueous layer, and discarding said first organic layer;

d) adjusting the pH of said first aqueous layer to 7.5-8.5; and

e) washing said first aqueous layer with a second non-polar organic solvent to form a second organic layer and a second aqueous layer, and discarding said second aqueous layer,

such that said alkylaminomethyl minocycline compound is purified.

2. The method of claim 1 , wherein said low pH aqueous solution has a pH of 2-3.

3. The method of claim 1 , wherein said low pH aqueous solution comprises methyl sulfonic acid.

4. The method of claim 1 , wherein said polar organic solvent is acetonitrile.

5. The method of claim 1 , wherein said pH in step b) or d) is adjusted with a base.

6. The method of claim 5 , wherein said base is selected from the group consisting of metal hydroxide, metal carbonate, metal bicarbonate, ammonia, organic primary amine, organic secondary amine and organic tertiary amine.

7. The method of claim 6 , wherein said metal is selected from the group consisting of lithium, sodium, potassium, calcium, magnesium and aluminum.

8. The method of claim 6 , wherein said base is sodium hydroxide or ammonia.

9. The method of claim 1 , wherein said first non-polar organic solvent is methylene chloride.

10. The method of claim 1 , wherein said first organic layer comprises by-products, hydrophobic impurities and oxidative degradents of said alkylaminomethyl minocycline compound.

11. The method of claim 1 , wherein said second non-polar organic solvent is methylene chloride.

12. The method of claim 1 , wherein said second aqueous layer comprises by-products and β epimer of said alkylaminomethyl minocycline compound.

13. The method of claim 1 , wherein an antioxidant is added.

14. The method of claim 13 , wherein said antioxidant is ammonium sulfite, sodium sulfite, bisulfite or meta bisulfite.

15. The method of claim 1 , wherein said alkylaminomethyl minocycline compound is:

wherein R A is alkyl, and R B is hydrogen or alkyl.

16. The method of claim 15 , wherein R B is hydrogen.

17. The method of claim 16 , wherein R A is alkyl.

18. The method of claim 17 , wherein said alkyl is (CH 3 ) 3 CCH 2 -.

19. The method of claim 1 , wherein said alkylaminomethyl minocycline compound is:

20. The method of claim 1 , wherein hydrophobic impurities and oxidative degradents are removed from said alkylaminomethyl minocycline compound.

21. The method of claim 1 , wherein by-products and β-C-4 epimer are removed from said alkylaminomethyl minocycline compound.

22. The method of claim 1 , wherein said alkylaminomethyl minocycline compound is essentially free of hydrophobic impurities and oxidative degradents.

23. The method of claim 1 , wherein said alkylaminomethyl minocycline compound is essentially free of by-products, β-C-4 epimer, hydrophobic impourities and oxidative degradents.

24. The method of claim 1 , wherein said alkylaminomethyl minocycline compound comprises at least 50% α-C-4 epimer.

25. The method of claim 24 , wherein said alkylaminomethyl minocycline compound comprises at least 95% α-C-4 epimer.

26. The method of claim 25 , wherein said alkylaminomethyl minocycline compound comprises at least 99.9% α-C-4 epimer.

27. The method of claim 1 , wherein said alkylaminomethyl minocycline compound comprises less than 7% β-C-4 epimer.

28. The method of claim 27 , wherein said alkylaminomethyl minocycline compound comprises less than 3% β-C-4 epimer.

Assignments (8)
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 71200/0656 Recorded Mar 17, 2026
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 075101/0815 →
PATENT SECURITY AGREEMENT Recorded Mar 16, 2026
From: PARATEK PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075111/0244 →
RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT REEL/FRAME 065001/0917 Recorded May 22, 2025
From: OAKTREE FUND ADMINISTRATION, LLC
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 071343/0407 →
SECURITY INTEREST Recorded May 22, 2025
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 071200/0656 →
SECURITY INTEREST Recorded Sep 22, 2023
From: PARATEK PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 065001/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2014
From: JOHNSTON, SEAN; WARCHOL, TADEUSZ
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034567/0904 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2014
From: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
To: PARATEK PHARMACEUTICALS, INC.
Reel/Frame 034113/0910 →
SECURITY INTEREST Recorded Mar 14, 2014
From: PARATEK PHARMACEUTICALS, INC.
To: HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD., AS COLLATERAL AGENT
Reel/Frame 032448/0001 →